Pular para o conteúdo principal
Ranking Invest

ALKS - Alkermes plc

Segmento: HealthcareAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Análise Ranking Invest

Valor de Mercado
$ 7.59 Bi
IVR
0.32Índice proprietário de comparação relativa: 0,32.
IVR2
0.10Leitura proprietária complementar: 10%.
MLL
0.10Leitura proprietária complementar: 10%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 1.81 Bi

Dívida Líquida

$ 1.01 Bi

L4T

$ 66.12 Mi

MM4T

4.25%

Indicadores Básicos

ROE

3.66%

Índices de Previsibilidade

Receita Líquida

D0.14

Lucro

E1.24

Margem

E1.71

Índices de Tendência

Receita Líquida

C3.73

Lucro

D0.25

Margem

C2.00

Índices de Endividamento

DIV/PAT

0.56

DIV/L4T

15.33

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.